Editorial: Empiric antimicrobial therapy of community-acquired pneumonia: Clinical diagnosis versus procalcitonin levels

Scandinavian Journal of Infectious Diseases

Volumn 41, Issue 10, 2009, Pages 782-784

  Cunha, Burke A ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CEFUROXIME; CLARITHROMYCIN; DOXYCYCLINE; PENICILLIN G; PROCALCITONIN; QUINOLONE; ANTIINFECTIVE AGENT; CALCITONIN; PROTEIN PRECURSOR;

ANTIMICROBIAL THERAPY; ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; EDITORIAL; EMPIRICISM; ENDOCARDITIS; HAEMOPHILUS INFLUENZAE TYPE A; HORMONE BLOOD LEVEL; HUMAN; LABORATORY TEST; MONOTHERAPY; NEUTROPHIL; PNEUMONIA; PROCALCITONIN BLOOD LEVEL; SEPSIS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT DURATION; BACTERIAL PNEUMONIA; BLOOD; COMMUNICABLE DISEASE; DIFFERENTIAL DIAGNOSIS;

ANTI-INFECTIVE AGENTS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PNEUMONIA, BACTERIAL; PROTEIN PRECURSORS; RADIOGRAPHY, THORACIC;

EID: 72449170128     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540903147035     Document Type: Editorial

References (10)

1. Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission*a randomized trial. Clin Microbiol Infect 2009;/15:/481-7.
2. Heflund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;/28:/68-73.
3. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome to lower respiratory tract infections: cluster-randomised single-blinded intervention trial. Lancet 2004;/363:/600-7.
4. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;/168:/2000-7.
5. Christ-Crain M, Muller B. Procalcitonin in bacterial infections* hype, hope, more or less. Swiss Med Wkly 2005;/135:/451-60.
6. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;/39:/206-17.
7. Cunha BA. Pneumonia essentials. 3rd ed. Sudbury, MA: Jones and Bartlett; 2009.
8. Cunha BA. Empiric therapy of community-acquired pneumonia. Chest 2004;/125:/1913-9.
9. JerebM, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006;/118:/170-4.
10. Damoiseaux R. PCT-guided antibiotic use in primary care: the ultimate proof still ahead. Arch Intern Med 2009;/169:/ 717-718